A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.

A Phase 1/1b First-in-human Study of BMS-986463 in Advanced Malignant Tumors

The purpose of this study is to evaluate the safety, tolerability, and efficacy of escalating doses of BMS-986463 in participants with select advanced malignant tumors.

Inclusion Criteria

• Participants must have an Eastern Cooperative Oncology Group Performance Status of 0 or 1.
• Participants must have at least 1 lesion accessible for biopsy in addition to the target lesion, from which a fresh pre treatment biopsy must be obtained.
• Participants must have an unresectable/metastatic carcinoma.

Exclusion Criteria

• Participants must not have Leptomeningeal metastases.
• Participants must not have concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 2 years prior to treatment.
• Participants must not have had any prior radiation therapy within 2 weeks prior to start of study treatment.
• Other protocol-defined Inclusion/Exclusion criteria apply.